Fluorescent tumor-targeted polymer-bioconjugate: A potent theranostic platform for cancer therapy

Publication date: Available online 1 April 2020Source: European Polymer JournalAuthor(s): Himani Kalita, Manoj Patowary
Source: European Polymer Journal - Category: Chemistry Source Type: research

Related Links:

AbstractPurposeComplementary and alternative medicine (CAM) use is common amongst cancer patients. However, there is growing concern about its safety and efficacy. Online crowdfunding campaigns represent a unique avenue to understand the cancer patient ’s perspective for using CAM or declining conventional cancer therapy (CCT).MethodsFive hundred GoFundMe campaigns from 2012 to 2019 detailing financial need for cancer treatment were randomly selected and reviewed for endorsement of CAM use, reasons for using CAM, and reasons for declining CCT. Descriptive statistics were used to compare patient and campaign character...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
AbstractThe purpose of this pilot study was to determine whether photobiomodulation (PBM) might be effective for chemotherapy-induced palmo-plantar erythrodyesthesia (PPED), as it is for mucositis or radio dermatitis; no standard therapy exists for PPED. Patients were allocated to PBM or sham irradiation and were blindly assessed after 2 weeks. Pain and satisfaction with treatment were also evaluated. We found a significant benefit from PBM in comparison with sham treatment (p
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
The Forever Healthy Foundation publishes a series of conservative risk-benefit analyses of presently available interventions that might prove beneficial in addressing aspects of aging. These range widely in proven effectiveness, quality of animal evidence, and theoretical utility. Some do not in any way attack the known root causes of aging. Some are still pending any sort of rigorous human trial data. Some have plenty of human data that strongly indicates small, unreliable effects at best. It is nonetheless a useful exercise to make clear which are which. In a world in which the "anti-aging" industry propagates ...
Source: Fight Aging! - Category: Research Authors: Tags: Of Interest Source Type: blogs
CONCLUSION: Fatigue represents a very profound and prolonged impairment for the patients of our study. Since fatigue can still be present a long time after completion of treatment, patients should be asked about it specifically using a standardized inventory during follow-up. In order to cope with fatigue syndrome, specific therapeutic recommendations aimed at activation, such as regular physical activity, nutritional advice, and complementary measures, can be made. PMID: 32451566 [PubMed - as supplied by publisher]
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research
Chemistry of MaterialsDOI: 10.1021/acs.chemmater.0c00615
Source: Chemistry of Materials - Category: Materials Science Authors: Source Type: research
(University of Texas Health Science Center at San Antonio) Fueled by genetic changes due to cancer therapy itself, rogue cells may become very large with twice or quadruple the number of chromosomes found in healthy cells. Dr. Daruka Mahadevan of the Mays Cancer Center, home to UT Health San Antonio MD Anderson, seeks to find drugs that prevent or treat this problem.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
(Worcester Polytechnic Institute) A team of researchers led by Worcester Polytechnic Institute Provost Wole Soboyejo attached anti-cancer agents to the hormone LHRH to create drugs that targeted triple-negative breast cancer, which typically does not respond to conventional targeted cancer therapies. The researchers reported that the treatments reduced the size of tumors in mice with no signs of toxic side effects.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Acta Pharmacologica Sinica, Published online: 28 May 2020; doi:10.1038/s41401-020-0422-6CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy
Source: Acta Pharmacologica Sinica - Category: Drugs & Pharmacology Authors: Source Type: research
AbstractPurpose of ReviewThe novel Coronavirus (2019-nCoV, COVID-19) is historically one of the most severe acute respiratory syndromes and pandemics to affect the globe in the twenty-first century. Originating in Wuhan, the virus rapidly spread and impacted subsets of populations with initial unclear risk factors contributing to worsening morbidity and mortality. Patients with diagnosis of cancer and undergoing treatment further represent a population at risk for worsening cardiopulmonary outcomes. This review explores specific risk factors, diagnoses, and treatment options that impact cardio-oncologic patients with COVID...
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
Conclusion: Luteolin-loading of Her-2-NPs could potentially be used as a novel anti-cancer drugs for targeted cancer therapy.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Chemistry